Gastrointestinal Cancer Articles

Expert Shares Insight on Navigating Neuroendocrine Tumor Treatment
Paul R. Helft, MD, discusses the incidence of gastrointestinal neuroendocrine tumors and available and emerging treatment methods.
Therapeutic Options Continue to Grow for HCC
Tanios Bekaii-Saab, MD, sheds light on the recent advances in the treatment of patients with hepatocellular carcinoma. 
Epacadostat Falls Short Again
Adding the IDO1 inhibitor epacadostat to the PD-L1 inhibitor durvalumab (Imfinzi) failed to induce any clinical responses in patients with pancreatic cancer.
Role of Immunotherapies Emerging in Gastric/GEJ Cancers
Andrew Ko, MD, discusses how the approval of pembrolizumab has impacted patients with positive PD-L1 expression and how clinical trials that have reshaped the standard of care in patients with gastric and GEJ cancers.
HCC Trials Spur Treatment Landscape Forward
R. Kate Kelley, MD, discusses the incidence of and risk factors for HCC, and emphasizes the sequence of clinical trials that characterized the field in 2017.
Tempero Spotlights Frontline Treatment Options in Pancreatic Cancer
Margaret A. Tempero, MD, discusseds frontline treatment options in pancreatic cancer and emphasized the use and difficulties of conventional and incoming therapies across disease states.
UCLA Oncologist Pursues Promise of CSF1R Inhibitor Combos
Zev A. Wainberg, MD, discusses data from the pancreatic cancer cohort of a trial evaluating cabiralizumab in combination with nivolumab.
Ramucirumab extended overall survival versus placebo as a second-line treatment for patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein, according to findings from the phase III REACH-2 trial.
 
Bekaii-Saab Highlights Emerging Agents in Pancreatic Cancer Pipeline
Tanios Bekaii-Saab, MD, discusses emerging treatments offering hope to patients with pancreatic cancer.
Precision Medicine Impact Grows in GI Cancer Paradigm
Bert H. O’Neil, MD, discusses the role of molecular testing throughout GI cancers and highlights the current and developing treatment landscape for patients with colorectal cancer. 
Publication Bottom Border
Border Publication
x